Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

T790M mutation

This page shows the latest T790M mutation news and features for those working in and with pharma, biotech and healthcare.

AZ speeds first-line lung cancer filing for Tagrisso to EMA

AZ speeds first-line lung cancer filing for Tagrisso to EMA

Tagrisso has been growing fast in its approved indication as a second-line therapy for EGFR-positive NSCLC after patients develop resistance (the T790M mutation) and progress on Iressa or Tarceva, ... Conversely, others argue that this denies patients

Latest news

  • AZ gets rapid approval in China for Tagrisso AZ gets rapid approval in China for Tagrisso

    Tagrisso (osimertinib) - a third-generation EGFR inhibitor - has been approved by the China Food and Drug Administration (CFDA) as a second-line treatment for EGFR T790M mutation-positive metastatic non-small ... Last December, AZ reported head-to-head

  • AZ's Tagrisso beats chemotherapy in lung cancer trial AZ's Tagrisso beats chemotherapy in lung cancer trial

    to standard therapy in patients with T790M mutation-positive, locally-advanced or metastatic NSCLC. ... Tagrisso is a third-generation EGFR inhibitor and was the first drug to be approved to treat patients with metastatic EGFR T790M mutation-positive

  • Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso

    In the meantime, the recently-relaunched CDF will give around 300 patients across England and Wales access to Tagrisso as a second-line treatment for advanced metastatic EGFR T790M mutation-positive ... This is the system working as it should.”.

  • FDA panel says no to quick approval of Clovis' rociletinib FDA panel says no to quick approval of Clovis' rociletinib

    Rociletinib is under review for the treatment of non-small cell lung cancer (NSCLC) patients whose tumours are epidermal growth factor receptor (EGFR) positive and carry the T790M resistance mutation. ... T790M is the most commonly encountered and

  • Japanese approvals for GSK, AZ and Bayer Japanese approvals for GSK, AZ and Bayer

    AZ has also got a green light in Japan for its third-generation EGFR inhibitor Tagrisso (osimertinib) for the treatment of patients with EGFR T790M mutation-positive inoperable or recurrent ... develop the T790M mutation.

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    resistance mechanisms for first and second generation inhibitors is the emergence of T790m, which basically switches on that same pathway again. ... Another development is AZD9291 – a drug which addresses the T790M mutation, which is a key resistance

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Quick links

Infographics

Multimedia